Table 2.
Clinical improvement in axSpA and axPsA after 6 and 12 months, according to ASDAS and PhyGA.
| 6 months | 12 months | |||||
|---|---|---|---|---|---|---|
| axSpA | axPsA | p-value | axSpA | axPsA | p-value | |
| Clinically important improvement ASDAS, n/N (%) | 118/227 (52) | 29/62 (47) | 0.6 | 109/192 (57) | 25/50 (50) | 0.4 |
| Major improvement ASDAS, n/N (%) | 64/227 (28) | 16/62 (26) | 0.8 | 62/192 (32) | 16/50 (32) | 0.4 |
| Clinical improvement PhyGA, n/N (%) | 108/165 (65) | 42/63 (67) | 0.9 | 100/154 (65) | 43/58 (74) | 0.2 |
Clinically important improvement ASDAS, delta-ASDAS ⩾1.1; major improvement ASDAS, delta-ASDAS ⩾2.0; clinical improvement PhyGA, improvement of at least 30% compared with baseline at the studied time points.
ASDAS, Ankylosing Spondylitis Disease Activity Score; axPsA, axial psoriatic arthritis; axSpA, axial spondyloarthritis; PhyGA, Physician Global Assessment.